Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma.

Oncotarget - 1 Oct 2012

Kannan Kasthuri, Inagaki Akiko, Silber Joachim, Gorovets Daniel, Zhang Jianan, Kastenhuber Edward R, Heguy Adriana, Petrini John H, Chan Timothy A, Huse Jason T

Abstract excerpt

The molecular foundations of lower-grade gliomas (LGGs)-astrocytoma, oligodendroglioma, and oligoastrocytoma-remain less well characterized than those of their fully malignant counterpart, glioblastoma. Mutations in isocitrate dehydrogenase 1 and 2 (IDH1/2) likely represent initiating pathogenic events. However, while IDH mutations appear to dramatically alter cellular epigenomic landscapes, definitive downstream...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to DNA Helicases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glioma

Share to In Situ Hybridization, Fluorescence

Share to Isocitrate Dehydrogenase

Share to Neoplasm Grading

Share to X-linked Nuclear Protein

Source

Open in PubMed Open full text

Identifiers

PMID: 23104868
DOI: 10.18632/oncotarget.689
PMCID: PMC3717947

Genes

ATRX
IDH1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma.PMID 23104868Read ↗

ATRX mRNA expression combined with IDH1/2 mutational status and Ki-67 expression refines the molecular classification of astrocytic tumors: evidence from the whole transcriptome sequencing of 169 samples samples.Semantic proximity Read ↗

New Molecular Considerations for Glioma: IDH, ATRX, BRAF, TERT, H3 K27M.Semantic proximity Read ↗

Functional Assessment of ATRX Alterations Improves Glioma DiagnosisSemantic proximity Read ↗

Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations.Semantic proximity Read ↗

Molecular Classification Defines 4 Prognostically Distinct Glioma Groups Irrespective of Diagnosis and GradeSemantic proximity Read ↗

Functional analysis of telomere maintenance mechanisms is more informative than immunohistochemistry for ATRX mutation interpretation in Gliomas.Semantic proximity Read ↗

Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas.Semantic proximity Read ↗

Determination of IDH1, IDH2, MGMT, TERT and ATRX Gene Mutations in Glial Tumors.Semantic proximity Read ↗

ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis.Semantic proximity Read ↗

The Role of ATRX in Glioma BiologySemantic proximity Read ↗

Atrx inactivation drives disease-defining phenotypes in glioma cells of origin through global epigenomic remodeling.Semantic proximity Read ↗

The alternative lengthening of telomere phenotype is significantly associated with loss of ATRX expression in high-grade pediatric and adult astrocytomas: a multi-institutional study of 214 astrocytomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.